Allena to highlight poster on design of URIROX-1 trial at ASN Kidney Week
Allena Pharmaceuticals announced that it will present clinical data characterizing the significant unmet need in patients with enteric hyperoxaluria in a poster presentation at ASN Kidney Week 2018, held October 23-27, 2018 in San Diego, CA. The poster presentation includes composite data, details on kidney stone burden, and case studies from 33 patients with enteric hyperoxaluria who enrolled across Allena's three Phase 2 clinical trials of reloxaliase. Data from these 33 patients confirmed that a majority experienced persistently high 24-hour urinary oxalate excretion, despite following standard-of-care guidance for diet and hydration. Among 20 patients for whom kidney stone burden was assessed by CT scan, 16 had at least one kidney stone detected at enrollment, with an average of three stones present. Additionally, 20% of patients presenting with KS had very large stones, which could require urological intervention. Also at ASN Kidney Week, Allena will present a poster describing the design of URIROX-1, its ongoing Phase 3 clinical trial evaluating reloxaliase in patients with enteric hyperoxaluria. Allena expects to report initial data from this trial in the second half of 2019. Pending ongoing interactions with the U.S. FDA, Allena expects to initiate URIROX-2, the second, larger Phase 3 clinical trial of reloxaliase in patients with enteric hyperoxaluria, in the fourth quarter of 2018.